Frontier in Antifungal Treatments Against Major Human Fungal Opportunistic Pathogen Candida Species and Medically Important Fungi
The extensive uses of antifungal agents to treat fungal infections have created a global public health issue of drug resistance. Candida species and other pathogenic mycoses are the leading causes of invasive fungal infections and high mortality rate in human population. A limited number of antifungal agents show fungicidal effect; repetitive uses of fungistatic drugs lead to the development of drug resistance. New antifungal agents with a broader spectrum of activity and novel mechanisms of action have been recently developed to fight against resistant fungal strains and clinical isolates. This would create a possibility to investigate antifungal combinations in vitro, in yeast and in animal models. If the drugs have different mechanisms of action, increased drug potency and efficacy with reduced toxicity may be rewarded. Recently, there are several investigational antifungal agents on repurposing drugs and natural products from different sources––plants, microbial, and marines––which may be considered when designing antifungal drug combinations. Imminently, more classes of antifungals from natural products may be added to the current antifungal armamentarium. Therefore, the new frontier of combination therapy and natural drug discovery should continue to be pursued with anticipation while excessive and repetitive antifungal usage shall be refrained.
KeywordsAntifungal Candida Combination therapy Drug resistance Natural product Yeast model
This work is supported by Thailand Research Fund, National Research Council of Thailand, and King Mongkut’s University of Technology Thonburi through the KMUTT 55th Anniversary commemorative fund.
- Alvarez-Miranda M et al 2003 Characterization of the mechanism of action of ES-285, a novel antitumor drug from Mactromeris poynyma. In Clinical cancer research. American Association for Cancer Research, PhiladelphiaGoogle Scholar
- Croteau R, Kutchan TM, Lewis NG (2000) Natural products (secondary metabolites). In: Biochemistry and molecular biology of plants, vol 24. West Sussex, Chichester, pp 1250–1319Google Scholar
- Dias DA, Urban S, Roessner U (2012) A historical overview of natural products in drug discovery. Meta 2(2):303–336Google Scholar
- Dutcher JD (1968) The discovery and development of amphotericin B. Chest 54:296–298Google Scholar
- Facts et al (2004) The review of natural products: formerly lawrence review of natural products published by facts and comparisons. Lippincott Williams & Wilkins, LondonGoogle Scholar
- Mann J (2000) Murder, magic, and medicine. Oxford University Press, New YorkGoogle Scholar
- O’Hagan D (1991) The polyketide metabolites. Ellis Horwood Ltd, ChichesterGoogle Scholar
- Rivero-Menendez O et al (2016) Triazole resistance in Aspergillus spp.: a worldwide problem? J Fungi (Basel, Switzerland) 2(3):21Google Scholar
- Robbins N, Wright GD, Cowen LE (2016) Antifungal drugs: the current armamentarium and development of new agents. Microbiol Spectr 4(5):903–922Google Scholar
- Salcedo M et al (2003) The marine antitumor compound ES 285 activates EGD receptors. In: Clinical cancer research. American Association for Cancer Research, PhiladelphiaGoogle Scholar
- Shao J et al (2016) Antiproliferation of berberine in combination with fluconazole from the perspectives of reactive oxygen species, ergosterol and drug efflux in a fluconazole-resistant Candida tropicalis isolate. Front Microbiol (7):1516Google Scholar
- Vandeputte P, Ferrari S, Coste AT (2011b) Antifungal resistance and new strategies to control fungal infections. Intl J Microbiol 2012Google Scholar